The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Using artificial intelligence to accelerate patient eligibility screening in clinical trials
In this video, Aaron Gerds, MD, Cleveland Clinic, Cleveland, OH, discusses the potential use of a medically trained large language model (LLM)-based end-to-end system to automate patient eligibility screening in clinical trials. Dr Gerds highlights the potential of this artificial intelligence (AI) system to efficiently identify eligible patients, particularly those with rare diseases, by leveraging natural language processing to screen patients across a health system, which can accelerate clinical trial enrollment and bring new treatments to patients faster. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
